Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

被引：4
|
作者：
Mosher, Rebecca [1 ]
Poling, Laura [1 ]
Qin, LiuLiang [1 ]
Bodyak, Natalya [1 ]
Bergstrom, Donald [1 ]
机构：
[1] MersanaTherapeutics, Cambridge, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B119
引用
收藏
页数：2
相关论文
共 34 条
  • [21] Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer
    Collins, Scott D.
    Shaw, Pamela S.
    Fessler, Shawn P.
    Wang, Jason
    Mosher, Rebecca
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [22] Target expression/efficacy relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an unselected series of Non-small Cell Lung Cancer (NSCLC) primary human carcinoma xenografts
    Mosher, R.
    Vogel, C.
    Shaw, P.
    Zielinski, D.
    Boesler, C.
    Muhleisen, A.
    Frances, D.
    Schipper, C.
    Cyr, M.
    Jarlenski, D.
    Jasani, B.
    Mcgillicuddy, D.
    Hailman, E.
    Schildhaus, H. U.
    Ruschoff, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E136 - E136
  • [23] Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers
    Lin, Kedan
    Rubinfeld, Bonnee
    Zhang, Crystal
    Firestein, Ron
    Harstad, Eric
    Roth, Leslie
    Tsai, Siao Ping
    Schutten, Melissa
    Xu, Keyang
    Hristopoulos, Maria
    Polakis, Paul
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (22) : 5139 - 5150
  • [24] Discovery and preclinical development of a highly potent NaPi2b-targeted antibody -drug conjugate (ADC) with significant activity in patient -derived non -small cell lung cancer (NSCLC) xenograft models
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Yin, Mao
    Gumerov, Dmitry
    Bollu, Reddy
    Conlon, Patrick
    Gurijala, Venu R.
    McGillicuddy, Dennis
    Stevenson, Cheri
    Ter-Ovanesyan, Elena
    Park, Peter U.
    Poling, Laura
    Lee, Winnie
    Devit, Michael
    Xiao, Dongmei
    Qin, LiuLiang
    Lowinger, Timothy B.
    Bergstrom, Donald A.
    [J]. CANCER RESEARCH, 2016, 76
  • [25] Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker- payload for treatment of solid tumors
    Xiao, Liang
    Lian, Wei
    Liu, Qigang
    Zong, Qing
    Song, Shuai
    Stann, Sasha
    Cai, Jiaqiang
    Xue, Tongtong
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [26] Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
    Moore, Kathleen N.
    Birrer, Michael J.
    Marsters, Jim
    Wang, Yulei
    Choi, YounJeong
    Royer-Joo, Stephanie
    Lemahieu, Vanessa
    Armstrong, Katy
    Cordova, Julie
    Samineni, Divya
    Schuth, Eva
    Vaze, Anjali
    Maslyar, Daniel
    Humke, Eric W.
    Hamilton, Erika P.
    Liu, Joyce F.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 631 - 639
  • [27] UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Hays, John L.
    Friedman, Claire Frances
    Lakhani, Nehal
    Anderson, Charles K.
    Buscema, Joseph
    Duska, Linda R.
    Hamilton, Erika P.
    Taylor, Sarah E.
    Carrington, Cassandra
    Burger, Robert Allen
    Werner, Theresa Louise
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
    Gerber, David E.
    Infante, Jeffrey R.
    Gordon, Michael S.
    Goldberg, Sarah B.
    Martin, Miguel
    Felip, Enriqueta
    Martinez Garcia, Maria
    Schiller, Joan H.
    Spigel, David R.
    Cordova, Julie
    Westcott, Valerie
    Wang, Yulei
    Shames, David S.
    Choi, YounJeong
    Kahn, Robert
    Dere, Randall C.
    Samineni, Divya
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Royer-Joo, Stephanie
    Lemahieu, Vanessa
    Schuth, Eva
    Vaze, Anjali
    Maslyar, Daniel
    Humke, Eric W.
    Burris, Howard A., III
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (02) : 364 - 372
  • [29] SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER
    Gerber, David
    Infante, Jeffrey
    Gordon, Michael
    Schiller, Joan
    Spigel, David
    Wang, Yulei
    Shames, David S.
    Choi, Younjeong
    Kahn, Robb
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel
    Burris, Howard
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1190 - S1191
  • [30] Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
    Banerjee, S.
    Oza, A. M.
    Birrer, M. J.
    Hamilton, E. P.
    Hasan, J.
    Leary, A.
    Moore, K. N.
    Mackowiak-Matejczyk, B.
    Pikiel, J.
    Ray-Coquard, I.
    Trask, P.
    Lin, K.
    Schuth, E.
    Vaze, A.
    Choi, Y.
    Marsters, J. C.
    Maslyar, D. J.
    Lemahieu, V.
    Wang, Y.
    Humke, E. W.
    Liu, J. F.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (04) : 917 - 923
1234